Trimel Pharma's sexual disorder drug effective in mid-stage study
May 28 (Reuters) - Trimel Pharmaceuticals Corp said its experimental sexual disorder drug increased the average number of orgasms in patients with Female Orgasmic Disorder in a mid-stage study.
The company said a 0.6 mg dose of the nasal drug, Tefina, showed a statistically significant increase in the number of orgasms in pre-menopausal and post-menopausal patients with the condition, compared with a placebo.
Female Orgasmic Disorder, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasm, leading to distress. (Reporting by Vrinda Manocha in Bangalore; Editing by Kirti Pandey)
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- Canada PM vows crackdown after capital shocked by fatal attacks |
- Man arrested after jumping White House fence, causing lockdown
- Probe: Athletes took fake classes at University of North Carolina
- U.S.-led air strikes killed 521 fighters, 32 civilians in Syria: monitor